GeneTex Cancer Immune Checkpoint Antibodies

Increasing knowledge of how cancer cells escape immune destruction has driven the evolution of cancer immunotherapy. In particular, studies describing how different immune checkpoints (including the PD-1 and CTLA-4 pathways) function to attenuate T cell anti-tumour activity have revealed novel opportunities for therapeutic intervention. Researchers have made promising strides in inhibiting these checkpoints to unleash the T cells’ tumour-killing potential.

Given that both radiotherapy and chemotherapy can also mobilise anti-tumour T cells, there is potential in checkpoint inhibition and other immunomodulatory approaches being combined with conventional modalities to maximise clinical outcomes for a number of malignancies.

GeneTex has over 60 Cancer Immune Checkpoint Antibodies to choose from, including key targets such as CTLA4, FOXP3, LAG3, OX40L and PD-L1, with validations across various applications including flow cytometry, immunofluorescence, immunohistochemistry and western blotting. The antibodies are suitable for researchers seeking products to investigate the immunomodulatory effects of checkpoint inhibitors on cancer malignancies.